相关实验视频
Updated: May 21, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
尿液L-FABP:用于评估糖尿病病发作和进展的新型生物标志物. 一个叙事审查
Ersilia Satta1, Felice Strollo2, Luisa Borgia3
1Nefrocenter Research Network, Cava de´ Tirreni, Italy.
尿肝类型脂肪酸结合蛋白 (uL-FABP) 可以早期检测糖尿病病 (DN) 的发病和进展. 这种生物标志物在传统标志物出现之前对糖尿病患者有用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 生物标志物研究 生物标志物研究
背景情况:
- 糖尿病病 (DN) 是糖尿病 (DM) 的一个主要并发症,增加了发病率和死亡率.
- 目前的诊断标志物,如专分泌率 (AER) 和膜过率 (GFR),可能无法检测早期的DN.
- 对于早期DN检测和管理,需要新的,易于获取的生物标志物.
研究的目的:
- 评估尿肝类型脂肪酸结合蛋白 (uL-FABP) 在预测和诊断DN的性能.
- 评估L-FABP在监测糖尿病患者DN进展中的实用性.
主要方法:
- 进行了一项文献综述,分析了21项选定的研究 (14个截面,10个纵向).
- 研究调查了L-FABP水平与1型DM (T1DM) 和2型DM (T2DM) 患者的DN发病,严重程度和进展之间的关联.
- 来自研究的数据包括患有常态白蛋白尿症和不同阶段的DN的患者.
主要成果:
- 截面研究表明,L-FABP与T1DM和T2DM的DN发病和严重程度相关.
- 在患有DN的患者中,L-FABP水平升高,即使在正常AER (常态白蛋白尿) 患者中也是如此.
- 纵向研究表明,基线的L-FABP预测了正常白蛋白T1DM患者的DN发病和DN进展,无论糖尿病类型如何.
结论:
- 尿-L-FABP是DNA管状损伤的敏感生物标志物,在AER变化之前可以检测到.
- uL-FABP可以识别早期的DN发病,并预测T1DM和T2DM的严重程度和进展.
- 对L-FABP的临床检测的可用性为门诊机构提供了一个用户友好的诊断工具.
更多相关视频
13:26Visualization and Quantification of Mesenchymal Cell Adipogenic Differentiation Potential with a Lineage Specific Marker
Published on: March 31, 2018
09:16Highly Sensitive Measurement of Glomerular Permeability in Mice with Fluorescein Isothiocyanate-polysucrose 70
Published on: August 9, 2019
相关概念视频
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...